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Abstract 
Background: Delivery of long-acting nanoformulated antiretroviral drugs (ARVs) to human 
immunodeficiency virus type one cell and tissue reservoirs underlies next generation antiretroviral 
therapeutics. Nanotheranostics, comprised of trackable nanoparticle adjuncts, can facilitate ARV delivery 
through real-time drug tracking made possible through bioimaging platforms. 
Methods: To model HIV-1 therapeutic delivery, europium sulfide (EuS) nanoprobes were developed, 
characterized and then deployed to cells, tissues, and rodents. Tests were performed with nanoformulated 
rilpivirine (NRPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI) used clinically to suppress or 
prevent HIV-1 infection. First, CD4+ T cells and monocyte-derived macrophages were EuS-treated with and 
without endocytic blockers to identify nanoprobe uptake into cells. Second, Balb/c mice were co-dosed with 
NRPV and EuS or lutetium177-doped EuS (177LuEuS) theranostic nanoparticles to assess NRPV biodistribution 
via mass spectrometry. Third, single photon emission computed tomography (SPECT-CT) and magnetic 
resonance imaging (MRI) bioimaging were used to determine nanotheranostic and NRPV anatomic 
redistribution over time. 
Results: EuS nanoprobes and NRPV entered cells through dynamin-dependent pathways. SPECT-CT and MRI 
identified biodistribution patterns within the reticuloendothelial system for EuS that was coordinate with 
NRPV trafficking. 
Conclusions: EuS nanoprobes parallel the uptake and biodistribution of NRPV. These data support their use 
in modeling NRPV delivery to improve treatment strategies. 
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Introduction 
Infection by the human immunodeficiency virus 
type 1 (HIV-1) requires lifelong daily adherence to 
antiretroviral therapy (ART). ART treatment 
suppresses viral replication, mitigates transmission, 
and delays acquired immunodeficiency syndrome 
(AIDS) onset. Lack of access to treatment, negative 
social stigma, and drug associated toxicities 
contribute to a nearly 41% regimen adherence failure 
rate [1, 2]. Indeed, in the absence of ART, HIV-1 
replicates continuously in virus target cells. These 
include CD4+ T lymphocytes and, to a lesser extent, 
mononuclear phagocytes (MP; monocytes, 
macrophages, and dendritic cells) promoting either 
long-lived cell reservoirs or selective cell death, 
respectively. Integration of proviral DNA in cells 








The means to improve antiretrovirals that maximally 
suppress HIV-1 replication or simplify pre-exposure 
prophylaxis (PrEP) drug regimens is of immediate 
need for viral therapy and prevention. 
Recent clinical trials demonstrate the 
effectiveness of nanoformulated antiretrovirals as 
long-acting HIV-1 maintenance and prevention 
therapies. These are combinations of long-acting 
rilpivirine (RPV), a non-nucleoside reverse 
transcriptase inhibitor [3], and the integrase strand 
transfer inhibitor (INSTI), cabotegravir (CAB) [4]. 
Once a month, or once every other month, dosing was 
demonstrated to be a non-inferior regimen to daily 
oral therapy [3-8]. Similar strategies were recently 
developed for other antiretrovirals [9, 10]. Indeed, 
encasing these drugs in polymer excipients facilitates 
a slow dissolution of drugs from intramuscular 
injection sites. Plasma drug levels of protease 
inhibitors (PI) ritonavir, indindavir, atazanavir (ATV) 
and the NNRTI, efavirenz, were raised 1.5-4 fold 
encased in poloxamer 188 excipients [11]. Despite 
simplified dosing regimens, suboptimal delivery of 
INSTI to lymph nodes [12] and sequestration of 
nucleoside reverse transcriptase inhibitors by adipose 
tissues [13] prompt concern for low-level viral 
replication in tissues despite maintaining 
undetectable levels of the virus in circulation. Thus, 
further characterization of antiretroviral nanoparticle 
biodistribution is warranted. 
Defining delivery for HIV-1 therapeutic agents 
to lymphoid tissues could aid in the design of more 
effective clinical outcomes. To this end, theranostics 
serve as a bridge between therapeutic and diagnostic 
tracking. Previous iterations of HIV-1 theranostics 
included spherical europium cobalt-ferrite (CFEu) 
[14] and bismuth sulfide nanorods (BSNRs) [15]. 
These particles, loaded with RPV [14, 15] or 
dolutegravir (DTG; an INSTI) [16], showed 
characteristics of enhanced particle uptake in 
macrophages. Real-time non-invasive tracking of 
nanoparticles biodistribution using fluorescence, 
magnetic resonance imaging (MRI), and single photon 
emission computed tomography (SPECT-CT) 
conferred by their metal cores or inserting radiolabel 
tags have allowed the prediction of drug 
biodistribution based on early bioimaging composite 
analyses [15]. 
Taken together, theranostics provide a platform 
to construct nanoparticles in pursuit of sustained HIV 
suppression, a prerequisite for viral elimination from 
organisms [17]. Herein, we tested the concept that 
theranostics and antiretroviral nanoparticles with 
similar sizes and shapes will display parallel 
biodistributions. A novel theranostic agent, europium 
sulfide (EuS), was deployed as a cellular uptake 
model. EuS nanoprobes elucidate a potential 
dynamin-mediated mechanism for direct nanoparticle 
endocytosis by CD4+ T cells, a principal target of 
HIV-1. Real-time and non-invasive molecular imaging 
also reveals the utility of EuS as companion particles 
for NRPV in trafficking nanoparticles to known 
reservoir tissues, such as the spleen. These advances 
signal how nanotheranostic agents may serve as 
surrogates to better design long-acting ART and 
clustered regularly interspaced short palindromic 
repeats (CRISPR) nanoformulations for therapeutic 
delivery and viral elimination. 
Methods 
Materials 
RPV was purchased from LeapChem 
(Hangzhou, China). RPV nanoformulations (NRPV) 
were manufactured using an Avestin EmulsiFlex-C3 
high-pressure homogenizer (Ottawa, ON, Canada). 
NRPV was prepared to replicate RPV LA developed 
by Janssen [18], as described previously [19]. 
UPLC-MS/MS parameters for drug concentration 
determinations were performed as reported [19] and 
are detailed in supplementary materials. 
L-α-phosphatidylcholine, Tween-80, europium (III) 
chloride hexahydrate, 1-dodecanethiol, oleic acid, and 
oleylamine were obtained from Sigma-Aldrich. 
177LuCl3 was obtained from the National Isotope 
Development Center, Oak Ridge National Laboratory, 
Oak Ridge, TN, USA. DSPE-PEG2000 was purchased 
from Corden Pharma. 
Cells 
CEM-ss CD4+ T cells (NIH AIDS Reagent 
Program #776) were cultured in RPMI 1640 
containing 2 mM L-Glutamine, 10% fetal bovine 
serum, and 100 U/mL penicillin plus streptomycin 
(PenStrep). Monocytes were obtained from human 
HIV-1/2 and hepatitis seronegative donor elutriation 
without person identifiers and was thus exempt from 
the University of Nebraska Medical Center (UNMC) 
Institutional Review Board review. Cells were 
differentiated into monocyte-derived macrophages 
(MDM) by culture in Dulbecco’s Modified Eagle 
Media (DMEM) containing 4.5 g/L glucose, 10% 
pooled human serum, 1000 U/mL macrophage 
colony-stimulating factor, 1% glutamine, 50 μg/mL 
gentamicin, and 10 μg/mL ciprofloxacin for 7 days. 
Animals 
Male Balb/c mice (8 weeks old) were purchased 
from Jackson Laboratories (Bar Harbor, Maine, USA). 
Animals were housed in the UNMC Comparative 
Medicine animal facility according to the Association 
for Assessment and Accreditation of Laboratory 




Animal Care guidance. The UNMC Institutional 
Animal Care and Use Committee approved all 
protocols related to animal experiments and were 
certified to have met the requirements and ethical 
guidelines set forth by the National Institutes of 
Health in handling laboratory animals for research. 
Synthesis of 177LuEuS particles 
Intrinsically radiolabeled 177LuEuS particles, 
were prepared by a solvothermal technique in an 
isolated radioactive workstation. Europium (III) 
chloride hexahydrate (0.2 mM, ~72 mg), oleic acid (0.5 
ml), and oleylamine (4 ml) were mixed in a glass vial 
and this mixture was stirred for 30 min, and 
completely dispersed by bath sonication. Then ~70 
mCi of 177LuCl3 and 1-octadecene (5 mL) were mixed 
in a separate vial and transferred to the europium- 
oleic acid-oleylamine (Eu-OA-OAm) mixture. 
1-Dodecanethiol (3.0 mL) was quickly added to the 
reaction medium. The mixture was sonicated for 15 
minutes to provide a completely homogenous 
mixture. After vigorous stirring for 10 min, the 
solution was transferred into a high safety 
Teflon-lined reactor placed in a stainless-steel 
autoclave reactor, sealed airtight, and heated at 290°C 
for 1 hour. The systems were then allowed to cool 
naturally to room temperature (around 8 hours). After 
reaching room temperature, the reactor was opened in 
a controlled radioisotope workstation. Fifty milliliters 
of ethanol were added, vortexed and sonicated. The 
solution was then centrifuged at 976 x g for 30 
minutes at 15°C. 177LuEuS particles were collected and 
purified by repeating the same ethanol washing 
process three times to remove non-reacted 
components. The radioactive concentration of 
gamma-ray emitting lutetium-177 in stock 177LuEuS 
was measured using a gamma counter (CRC®-25R 
dose calibrator, Capintec, Inc, Florham Park, NJ, USA) 
(activity was ~ 60 mCi). Lipid coated 177LuEuS 
particles were prepared by thin-film dispersion 
technique. First, 100 mg L-α-phosphatidylcholine and 
50 mg DSPE-PEG2000 were dissolved in a 
chloroform/hexane mixture (5:1 v/v) contained 
within a round-bottomed flask and evaporated to 
form a thin film using a rotavap (Heidolph, Hei-VAP 
Precision; G3B Vertical, USA). The films were dried 
under vacuum overnight to complete the removal of 
organic solvents. Second, 177LuEuS particles were 
dispersed in chloroform (4 mL) followed by bath 
sonication for ~ 10 min to get a uniform dispersion of 
the particles in the solvent. The 177LuEuS- chloroform 
dispersion was mixed with 3 mL of 2% (v/v) 
Tween-80 in a 25 mL round-bottom flask and 
sonicated for 5 minutes to form a turbid metalosome 
emulsion. Third, chloroform was removed from the 
177LuEuS/chloroform/Tween-80 emulsion by 
rotaevaporation. Lastly, the 177LuEuS particle solution 
was transferred to the lipid film-coated round- 
bottomed flask and dispersed in the lipid film 
through gentle rotation at 35°C with continuous bath 
sonication. Lipid coated 177LuEuS was used for 
radioactivity analyses. Non-radiolabeled EuS particles 
were synthesized by the same procedure lacking 
177LuCl3 as a reactant. 
Radiolabeled particle stability 
The in vitro stability of lipid coated 177LuEuS 
particles was determined by spiking 10.2 μCi (~ 100 
μL) of 177LuEuS in tubes containing 400 μL Balb/c 
mouse serum incubated at 25°C or 37ºC for seven 
days. The samples were centrifuged at 77,474 × g for 
30 minutes at 10ºC. The supernatant was collected 
into a separate microcentrifuge tube. The radioactivity 
in the pellet and the supernatant was measured by 
gamma counter. To determine percent stability the 
following equation was used: Radiolabeling stability 
(%) = radioactivity in pellet/total radioactivity (pellet 
plus supernatant) × 100. 
Cellular uptake of NRPV and EuS 
For CD4+ T cell studies, individual wells of 
12-well tissue culture plates were precoated with 100 
μg/mL poly-L-lysine for one hour and then the 
contents were removed and washed once with sterile 
PBS. CEM-ss CD4+ T cells or MDM were seeded in 
12-well plates at 1 × 106 cells / well in 1 mL media. 
The non-cytotoxic concentration of EuS was 
determined by absorbance at 490 nm after cells were 
treated with serially diluted EuS for 24 hours, 
followed by 2-hour incubation with 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 
1 mg/mL). T cells and MDM received lipid-coated 
EuS particle treatments at 10 ppm and 100 ppm of 
Eu-153 (Eu153), respectively. Chemical inhibitors were 
spiked into appropriate wells at final concentrations 
of 30 μM Pitstop2, 100 μM Dynasore, or 4 μM CK666. 
At designated time points, supernatants were 
discarded, and cells were washed 3× with 1 mL PBS 
and counted by trypan blue exclusion staining. After 
that, collected contents were centrifuged 650 × g for 5 
minutes at 4°C to pellet nanoparticle-containing cells. 
Pellets were stored for quantitation of inorganic 
material (ICP-MS) or drug (UPLC-UV/Vis), as 
detailed in supplemental materials. 
177LuEuS biodistribution 
SPECT-CT imaging was performed on mice to 
assess the in vivo biodistribution of 177LuEuS particles. 
Each animal was dosed by tail-vein injection with ~ 
500 μCi of 177LuEuS (volume of injection: 170 μL) plus 
45 mg/kg NRPV (volume of injection: 100 μL). Images 




were acquired at 6, 12, 24, 48, and 120 hours post 
injection using a SPECT-CT system (Flex Triumph, 
TriFoil Imaging, Northridge, CA, USA) fitted with a 
five pinhole (1.0 mm per pinhole) collimator. CT 
images were acquired using 360 projections over 360° 
with an X-ray tube current of 140 mA and voltage of 
75 kilovoltage peak (kVp) at a magnification of 2.0 
(field of view = 59.2 mm2). Immediately after, SPECT 
image acquisition was performed with the following 
parameters: 64 projections at 15 seconds per 
projection over 360° using a radius of rotation of 48 
mm (field of view = 59 mm2). Co-registration of 
anatomical CT images and functional SPECT was 
performed by 3D visualization and analysis software, 
VivoQuant 3.5 (Invicro Boston, MA, USA). Regions of 
interest (ROIs) were drawn over various organs and 
radioactivity content and organ volumes were 
determined and used to calculate counts per cubic 
millimeter (mm3). Mice were sacrificed 5 days 
post-injection. Heart, lungs, liver, pancreas, stomach, 
spleen, small intestine, large intestine, kidneys, 
bladder, lymph nodes, muscle, bone, brain, testes, 
injection site (tail) and blood were collected, weighed, 
and analyzed for radioactivity using gamma 
scintillation spectrometry (ORTEC NaI(Ti) 
Scintillation Radiation Detector, Ametek, Oak Ridge, 
TN, USA). Additionally, animals were individually 
caged so that excreted signal could be measured from 
the bedding. Signal measured was back calculated to 
the injection time to account for the radioactive decay 
of 177Lu (t1/2 = 6.64 days). The signal from each tissue 
was normalized to the sum of total counts from all 
sources and then divided by the weight of the organ 
to obtain % injected dose (ID)/g for each tissue. 
MRI relaxivity measures 
EuS particle phantoms for MRI measures were 
prepared as previously reported [20]. MRI data were 
acquired on a 7T/16 cm Bruker PharmaScan MRI 
system (Bruker; Ettlingen, Germany). For T2 map 
measurements, CPMG (Carr Purcell Meiboom Gill 
sequence) phase-cycled 3-dimensional multi-echo 
sequence data was acquired with 250 ms repetition 
time, 48 echoes (echo times TEn = n X 2.618; n = 
1,…,48), 128 × 128 × 64 acquisition matrix, 70 × 64.76 × 
42.38 mm FOV, one average, for a total scan time of 34 
min. 
Animal MRI 
Animal MRI was performed on a 7T/16 cm 
Bruker PharmaScan MRI system. Mice were 
anesthetized with isoflurane in 100% oxygen and 
maintained at 40-80 breaths per minute. Animals were 
scanned by MRI prior to or after dosing with EuS (17 
mg/kg, tail vein injection). T2-relaxtion maps were 
generated using a CPMG phase-cycled multi-echo 
multi-slice sequence. Data were acquired with 3000 
ms repetition time, 50 echoes (echo times TEn = n × 10 
ms; n = 1), 256 × 128 acquisition matrix, 25 × 25 mm 
FOV, slice thickness = 0.5 mm, 2 averages, for a total 
scan time of 13 min. T2 signal in liver, spleen, and 
kidneys was quantified by densitometry of ROI 
pixilation in ImageJ v1.51m9 (National Institutes of 
Health, USA) [21] and converted to ΔR2 as 
1000/(T2post-treatment – T2pre-treatment). 
Statistical analyses 
Linear regressions and statistics were calculated 
in GraphPad Prism v7.0 (La Jolla, CA) as described in 
the figure legends. Data are depicted as mean ± 
standard error of the mean (SEM) of biological 
triplicates. Statistical significance was measure by 
two-way ANOVA with Bonferroni corrections for 
multiple comparisons. 
Results 
Synthesis and characterization of radiolabeled 
EuS (177LuEuS) nanoparticles 
Intrinsic “chelator-free” and non-leachable 
radiolabeled europium sulfide (177LuEuS) was first 
synthesized by solvothermal precipitation of 
europium (III) chloride hexahydrate and 
1-decanethiol in the presence of oleic acid, oleylamine 
and octadecene with 177LuCl3 at 290°C (Figure 1A). 
Parallel reactions were performed without 177LuCl3 to 
enable non-radioactive experiments. Lipid coatings 
containing L-α-phosphatidylcholine and 
DSPE-PEG2000 were used to make biocompatible lipid 
coatings for EuS particles. Transmission electron 
microscopy (TEM) revealed that EuS nanocrystals had 
rod shapes of 25 nm in diameter by ~ 350 nm in length 
(Figure 1B). These approximate the 250 nm and 350 
nm hydrodynamic diameters of NRPV, and RPV 
prodrug formulations (NM3RPV) as described 
previously [19]. High resolution (HR)-TEM images 
(Figures 1C-E) show the lattice fringes with spacings 
of 0.36-0.37 nm. High-angle annular dark-field 
scanning TEM (HAADF-STEM) illustrates europium 
(Eu; red) and sulfur (S; green) as an approximate 
70%:30% composition (Figure 1F). 
The X-ray diffraction (XRD) shown in Figure 1G 
reveals that all peaks are indexed into a cubic crystal 
and reconfirmed with the JCPDS file for Eu and S or 
bulk EuS (JCPDS file numbers; 01-073-6349;26-1419; 
05-001-0200; 04-007-2069). The XRD peaks of 14.5°, 
15.0°, 17.0°, 25.0°, 27.3°, 29.35°, 31.6°, 34.7°, 40.5°, 
41.85°, 43.8°, 46.63° and 50.9° at 2θ are typical 
indications for face-centered cubic planes of EuS 
crystal structure. For example, space group (111 = hkl) 




lattice spacing approximate 3.6 Å = 0.36 nm, 
corresponding to 25.0° in 2θ and 0.36 nm spacing 
obtained through HR-TEM (Figures 1C-E). The 
energy dispersive X-ray spectroscopy (EDX) analysis 
demonstrated “europium” and “sulfur” signals were 
detected in the EuS nanoprobes (Figure 1H). Results 
cumulatively illustrate successful synthesis of 
rod-shaped nanoprobes whose elemental core 
constituents are readily detectable after formulation. 
Multimodal trackability of EuS Nanoparticles 
To ascertain the potential of EuS as surrogates 
for NRPV tracking in vivo, the nanoprobes were tested 
for compatibility with a range of bioimaging 
modalities. Fluorescence provides a sensitive means 
of detection across short distances. Fluorescent blue 
spectra for EuS revealed maximal excitation and 
emission wavelengths at 410 nm and 510 nm, 
respectively (Figure 2A). EuS fluorescence is due to 
electron transitions from the 4f7 ground state to 4f6 
5d1 excited state (Eu(II)) [22]. Similarly observed 
results from europium-containing nanotubes have 
been attributed to a +2-oxidation state that yields blue 
light upon UV wavelength excitation [23]. 
 
 
Figure 1. Synthesis and characterization of EuS particles. (A) Synthesis scheme of EuS particles. 1-Dodecanethiol served as a reducing agent plus sulfur precursor; the vial 
shows particle fluorescence. (B) Low-resolution TEM image of EuS is illustrated. The EuS dimensions were approximately 25 nm in diameter by ~ 350-500 nm in length. (C) 
HR-TEM images of a single EuS particle with lattice planes of 0.37 nm, corresponding with XRD data. (D-E) The selected area electron diffraction (SAED) pattern of EuS show 
characteristic interplanar spacing of the EuS single crystal structure. (F) The europium (red) and sulfur (green) element STEM mapping showed element localization within the 
particles by corresponding high-angle annular dark-field electron microscopy. (G) XRD patterns, correlating with HR-TEM lattice pattern and SAED data sets, confirmed the 
particles’ structural configurations. (H) Chemical composition of EuS particles assessed by EDX qualitatively demonstrated the particle elements. 





Figure 2. Intrinsic tracking properties of europium sulfide (EuS) nanoprobes. (A) Fluorescence spectra of resuspended EuS at λmax 410 nm excitation. (B) R2 
relaxation rate (inverse T2 value) was determined using serial dilution of EuS phantom particles in agar matrix. (C-F) Integrity of 177Lu intrinsic doping in EuS nanoparticles was 
determined by dosimetry. (C-D) Stability was calculated by normalizing radioactivity of experimental pellets against those of control. (E-F) The half-lives of 177LuEuS were 
calculated using one-phase decay algorithms of radiation levels across times using GraphPad Prism v7.0. 
 
Intact NRPV likewise emits fluorescence, albeit 
at a shorter wavelength (385 nm), resulting from 
aggregation induced emission [24]. The MRI 
compatibility of EuS was also determined as a means 
of quantifying particle accumulation at different 
tissue depths. At issue lies the propensity of f  d 
transition block electrons to preferentially oxidize 
Eu2+ to Eu3+, whose MRI relaxivity is short-lived [25]. 
The T2-weighted relaxivity constant of EuS 
nanoprobes measured 0.5177 ppm/second and 
showed strong linear correlation with europium 
concentration (Figure 2B). High T2-weighted 
relaxivity paired with blue wavelength emission 
suggests coordinated electron stability conferred to 
europium by sulfide atoms. Finally, gamma-ray 
emitting 177Lu was intrinsically doped into the cores of 
EuS nanoprobes to provide a final means of sensitive 
biotracking via SPECT-CT. The particle stability and 
half-life of 177LuEuS was found to be ~3.4 days under 
physiological conditions (37oC in serum matrix), 
which represents a 45-50% reduction from the 
half-lives of control-incubated sample (6.2 days) and 
native 177Lu (6.7 days) (Figures 2C-F). The 
radioactivity profile of 177LuEuS indicates that the 
nanoprobes are compatible with SPECT-CT imaging 
over a short duration. 
Endocytic Pathways of EuS Nanoparticle 
Uptake 
We next examined the propensity for HIV-1 
infectible CD4+ T cells and monocyte-derived 
macrophages (MDM) to endocytose EuS 
nanoparticles. A non-cytotoxic concentration of 10 
ppm Eu153 was determined by mitochondrial vitality 
assay over 24 hours in CEM-ss CD4+ T cells (Figure 
3A). A time course of EuS nanoparticle uptake in 




CEM-ss cells revealed 52% uptake of 10 ppm Eu153 
treatment by 24 hours (Figure 3B). The one-site 
saturation kinetic modeling of EuS uptake indicates 
delayed nanoparticle entry that becomes apparent 
between 4 and 8 hours post-treatment. To investigate 
a possible mechanism for EuS nanoprobe endocytosis 
by CD4+ T cells, a 24-hour uptake experiment was 
repeated in the presence of chemical inhibitors. 
Clathrin, dynamin, or actin related protein 2/3 (Arp 
2/3) complexes were blocked with Pitstop2 [26], 
Dynasore [27], or CK666 [28], respectively. Dynamin 
blockade with Dynasore elicited reductions in NRPV 
(50%) and EuS (35%) uptake (Figure 3C-D). 
Notably, clathrin inhibition by Pitstop2 also 
attenuated NRPV accumulation in CD4+ T cells 
(Figure 3C). The reduction of EuS uptake with 
dynamin inhibition (Figure 3D) paired with the 
appearance of endocytic pits by TEM (Figure 3E) 
suggests that caveolin rather than clathrin or actin line 
the cytoplasmic surface of CD4+ lymphocyte cellular 
invaginations [29]. 
Macrophages, which serve as long-term depots 
for nanoformulated antiretroviral prodrugs, were 
likewise assayed for phagocytosis of EuS. MTT 
 
 
Figure 3. Dynamin-mediated endocytosis of EuS nanoparticles by CEM-ss T cells. (A) EuS cytotoxity in CEM-ss T cells after 24-hour incubation was determined by 
MTT assay. (B) Time course of EuS uptake when treated at 10 ppm Eu153 was measured by ICP-MS. Saturation kinetic curve was fitted to experimental data using 1-site saturation 
curve in GraphPad Prism v7.0. (C-D) The mechanisms of NRPV and EuS nanoparticle uptake were assessed by pre-treating with clathrin-inhibitor (Pitstop2, 30 µM), 
dynamin/caveolin-inhibitor (Dynasore, 100 µM), or actin-mediated active transport inhibitor (CK666, 4 µM). (E) Transmission electron micrographs of CEM-ss T cells in the 
absence (left) or presence (center) of EuS. Far right micrograph (inset of center) depicts nanoparticle within endocytic pit. Bar graphs depict mean ± SEM of three biological 
replicates. Statistical differences were determined using two-way ANOVA between groups with a Bonferroni's post hoc-test to correct for multiple comparisons. *p < 0.05; ns: 
non-significant. 




assessment indicated no decline in mitochondrial 
vitality at concentrations up to 100 ppm Eu153 (Figure 
4A). MDM displayed maximal uptake between 2-4 
hours post treatment, with 28% of the added EuS 
particles taken up by the cells by 4 hours (Figure 4B). 
These levels approximate the 10% NRPV uptake 
reported in MDM previously [24]. Co-treatment with 
Dynasore significantly reduced EuS uptake in MDM 
by 40% (Figure 4C). Together, these data point to 
enhanced and rapid uptake of EuS by macrophages in 
a caveolin-dependent manner. 
EuS nanoparticle real time biodistribution 
Intrinsically doped 177LuEuS particles were 
assessed for their acute biodistribution upon 
intravenous (IV; via tail-vein) injection. To accelerate 
redistribution from muscle depots formed by long- 
acting antiretroviral intramuscular administration, 
mice were dosed sequentially with NRPV (45 mg/kg) 
followed by EuS nanorods (~500 μCi 177LuEuS/mouse 
or 17 mg Eu153/kg) via tail-vein injection. Bioimaging 
by SPECT-CT revealed an initial accumulation of 
nanoprobes in lungs by 24 hours (Figure 5A-B). This 
finding was unexpected but indicative that the 
300-500 nm length of our particles likely caused them 
to become entrapped in pulmonary capillaries during 
IV administration. By 48 hours, 177LuEuS were readily 
imaged in known HIV-1 anatomic reservoirs 
including spleen, liver, lungs, colon, and lymph 
nodes. SPECT-CT performed 5 days post-dosing 
illustrated the highest accumulation of 177LuEuS in 
spleen. 
An extended 30-day time course was used to 
examine EuS nanoprobe biodistribution via MRI. 
T2-weighted images revealed initial accumulation of 
EuS in liver two days post dosing, with significant 
redistribution to spleen between days 10 and 30 
(Figure 5C). The limitations of T2 contrast nanoprobes 
was observed by the lack of enhancement in lungs, 
ileum, colon, lymph nodes and brain. These results 
highlight the value in designing rod-shaped 
nanoparticles for trafficking payloads to the spleen, a 
known secondary lymphoid organ. 
EuS accumulation in organs approximates 
NRPV biodistribution 
Comparative analyses were performed to 
determine the utility of EuS nanoprobes as predictive 
biotrackers for NRPV distribution. Organs collected at 
sacrifice 5 days post-dosing revealed greatest 
accumulation of RPV in spleen (313 ng/g tissue), lung 
(257 ng/g tissue), lymph nodes (174 ng/g tissue), and 
liver (78 ng/g tissue) (Figure 6A). 
 
 
Figure 4. EuS uptake in human monocyte-derived macrophages (MDM). (A) EuS cytotoxicity in MDM after 24-hour incubation was determined by MTT assay. (B) 
Time course of EuS uptake of cells treated with 100 ppm Eu153 over 24 hours as measured by UPLC-TUV. The saturation kinetic curve was fitted to experimental data using 1-site 
saturation curve in GraphPad Prism v7.0. (C) The mechanism of nanoparticle uptake was assessed by pre-treating with Pitstop (30 µM), Dynasore (100 µM), or CK666 (4 µM) 
endocytic inhibitors. Graphs depict mean ± standard error of the mean (SEM) of three biological replicates. Statistical differences were determined using two-way ANOVA 
between groups with a Bonferroni's post hoc-test to correct for multiple comparisons. *p < 0.05; ns: non-significant. 





Figure 5. Europium-sulfide (EuS) nanoparticles redistribute to spleen. Male Balb/c mice (n = 5) were tail vein injected with ~ 500 µCi 177LuEuS nanoparticles (17 mg/kg 
europium-153) or EuS (17 mg/kg europium-153) plus NRPV (45 mg/kg). (A) SPECT-CT images and (B) signal concentrations in ROIs were processed using VivoQuant v3.5 
(Invicro Imaging Software) based on anatomy observed in plain CT. (C) Differences in R2 relaxivity after dosing (ΔR2) based on densitometry in ROIs drawn in ImageJ were 
calculated. Plots represent averages ± SEM. 
 
Europium-153 concentrations were also 
observed to be highest in the spleen (428 μg/g tissue), 
lung (525 μg/g tissue), and liver (73 μg/g tissue) by 
day 5 as measured by ICP-MS (Figure 6B). Parallel 
findings were observed using gamma-ray scintillation 
counting, which reflects 177Lu content (Figure 6C). 
Lower metal contents observed in lymph nodes at day 
5, as compared to RPV, could result from variability in 
the sizes and locations from which lymph nodes were 
collected at the time of harvest. 
Mass spectrometry quantitation for drug and 
metals performed at day 30 post-dosing revealed 
similar accumulations to those found at day 5. In 
particular, RPV was readily detectable in spleen (33 
ng/g tissue), liver (9.3 ng/g tissue), and lungs (5 ng/g 
tissue) (Figure 7A). Europium-153 measured 1409 
μg/g tissue in spleen, 223 μg/g tissue in liver, and 95 
μg/g tissue in lungs (Figure 7B). Replicate values for 
NRPV and EuS in colon and brain approached assay 
detection limits. The comparable distribution of both 
particles to macrophage rich organs suggests 
phagocytic processes are vital in determining the 
biodistribution of theranostics. 
Pearson correlations validated the significance of 
these trends at early and late timepoints. Spleens from 
dual-treated mice demonstrated a correlation between 
RPV and europium-153 concentrations (p = 0.0498; 
Figure 6D). This may relate to differences in organ 
perfusion or overall animal health in the context of 
dosing with radioactive materials. Meta-analysis from 
terminal sacrifice also displayed a significant 
correlation (p < 0.0001) between rilpivirine and 
europium-153 present in each organ (Figure 7C). As 
the high accumulation of both EuS and NRPV in 
spleen anchored this trend, it is possible that the 
utility of EuS in predicting drug content deposits in 
organs that serve as minor depots for ART is limited. 





Figure 6. Quantitative analysis of RPV and EuS in mouse tissues 5 days post-dosing. (A) NRPV drug concentration was measured in various tissues by UPLC-MS. (B) 
Europium-153 concentration was quantitated by ICP-MS. (C) Gamma-ray emission from collected tissues was measured after briefing radioactive decay by scintillation counting. 
(C) Raw radioactivity was divided by total radioactivity in all tissue measured per animal, giving percent injected dose, which was further normalized against tissue weight (% ID/g). 
(D) Pearson correlation between NRPV drug concentration values and europium-153 was determined in day 5 spleen samples. 
 
Figure 7. EuS correlates with NRPV biodistribution 30 days post-dosing. (A) NRPV drug concentration was measured in various tissues by UPLC-MS/MS. (B) 
Europium-153 concentration was quantitated by ICP-MS. (C) Day-30 Pearson correlation was calculated between average RPV drug concentration and europium-153 
concentration for each organ. 





Long-acting antiretroviral nanoformulations 
serve to improve therapeutic outcomes for treatment 
of HIV-1 infection and for prevention through PrEP. 
We posit that the development of such therapeutics 
can be accelerated through nanotheranostics. Here, 
defining delivery of drugs to cell and tissue reservoirs 
could lead to improved viral suppression, reduced 
transmission and CRISPR-associated HIV-1 
elimination. As a first step to achieve these goals we 
investigated the delivery of the newly United States 
Food and Drug Administration approved long acting 
antiretrovirals. This includes RPV, which with CAB, 
has demonstrated non-inferiority as part of HIV-1 
maintenance therapy [3]. Given that long-acting ART 
injections are not indicated for induction therapy, we 
sought to characterize RPV nanoparticles’ ability to 
reach viral reservoir target sites. Sensitive nanoprobes 
with bioimaging capabilities offer a surrogate means 
to trace antiretroviral biodistribution while reducing 
the cost, labor, and time otherwise required to survey 
drug concentrations at tissues of interest. Herein, we 
validated the utility of EuS nanoparticles as mimetics 
for NRPV cellular uptake and biodistribution. 
Although macrophages readily phagocytose 
antiretroviral nanoparticles, ART efficacy is in part a 
property of cellular uptake. Prior works revealed that 
rod-shape, use of poloxamer excipients, and surface 
decoration with folate, all modestly enhance ART 
nanoparticle uptake by macrophages [30, 31]. 
Theranostics have recapitulated these findings [16, 
20]. Here we present dynamin/caveolin as a primary 
endocytic pathway for nanoparticle entry into MP, 
distinct from previously reported clathrin-mediated 
endosomal trafficking of protease-inhibitor 
nanoparticles [32, 33]. Nanoformulated drugs 
accumulate in late endosomes where HIV-1 virions 
are present in high abundance [33, 34]. Antiretroviral 
prodrug nanoformulations are also present in high 
abundance within late- and recycling endosomes [35, 
36]. We postulate that while nanoformulated 
antiretrovirals and long-acting prodrugs both meet 
their targets in endosomes, prodrugs are hydrolyzed 
to their active forms under increasingly acidic late 
endosomal and lysosomal microenvironments [37] 
whereas native ART become degraded. HIV-1 and 
antiretroviral drug nanoparticles employ recycling 
endosomes for sustained release from cells [38]. 
Accordingly, all therapeutic nanoparticles for HIV-1 
treatment should be engineered to withstand 
acidification in late endosomes. 
An alternative to macrophage-mediated delivery 
rests in the direct uptake of particles by CD4+ T cells. 
As dynamin but not clathrin blockade significantly 
impeded EuS and NRPV uptake, we conclude that 
CD4+ T cells endocytose nanocrystals in caveolin- 
coated pits which operate in tandem with dynamin 
“pinching” of invaginated surfaces during endocytic 
vesicle formation. This finding accords with other 
studies that describe dynamin-2 as critical in CD4+ T 
lymphocyte endocytosis of T cell receptors [39] and 
HIV-1 [40]. Dynamin-2 enables HIV-1 transmission 
between adjacent T cells [40] and triggers appropriate 
clonal expansion via mTOR-cMyc signal cascades 
when TCR encounters cognate antigen [39]. As such, 
dynamin likely serves as an important cytoskeletal 
protein involved in transmission of vesicle-bound 
materials within its limited cytoplasm. Inclusion of 
rare earth metals, like europium, in therapeutic 
nanoparticles would confer the ability to track its 
migration through T cells’ endosomal network via 
fluorescence. 
Theranostic drug particles play an essential role 
in tracking therapeutic cargo in vivo. The rod shape 
and size of EuS matches the morphology of NRPV but 
maintains inherent fluorescent and magnetic 
properties. EuS was modified with lipids and 
transformed from lipophobic to lipophilic to expand 
tracking. The simplified EuS design, which eliminates 
the need for transition metals to complex with 
europium, conferred predictive multimodal 
trackability over a month. Unlike previous 
nanoprobes bearing cobalt-ferrite cores [14, 16], sulfur 
atoms sufficiently stabilize the europium (II) 
oxidation state. This enhanced its blue-wavelength 
fluorescence and T2-weighted contrast capabilities. 
Sulfur is a preferred coordinate binding partner to 
other inorganic elements as a result of its high 
biocompatibility [41, 42], antioxidant capacity [43], 
and low cost. Europium-153 concentrations correlated 
with RPV content in macrophage rich organs 
including spleen, liver, and lungs. Accordingly, EuS 
proved useful as a surrogate for RPV concentration 
for up to 30 days, particularly in splenic tissues. Non- 
invasive SPECT-CT and MRI revealed nanoprobe 
redistribution from lung to macrophage-rich tissues 
including liver and spleen. Our prior studies showed 
detectable RPV levels in liver, spleen, lymph nodes, 
and gut for up to 56-days following intramuscular 
injection of NRPV [19]. The perfusion of alveolar 
macrophages in lung, Kupffer cells in liver, and 
marginal zone macrophages in spleen likely underlie 
the biodistribution of EuS and NRPV. Although EuS 
were observed in lower quantities within lymph 
nodes as compared to NRPV, EuS is still likely to be 
present in the splenic periarteriolar lymphoid sheath 
(PALS) that is rich in CD4+ T cells [44]. High density 
177Lu signal emanating from the spleen at day 5 and 
T2-weighted contrast at day 30 may also indicate that 




marginal zone- and red-pulp macrophages readily 
engulf EuS nanoprobes. In summary, EuS nanoprobes 
whose size and shape approximates that of NRPV 
display similar trafficking to spleen. 
Although similarities were found between 
NRPV and EuS accumulation in spleen, liver and lung 
it is worth noting significant biodistribution 
disparities exist in other organs. Prior studies have 
demonstrated high RPV levels in kidney and gut 
exceeding those of spleen and liver 56 days after 
intramuscular dosing with poloxamer-encapsulated 
NRPV [19]. By contrast, intravenous co-dosing of 
bismuth-sulfate nanorods (BSNRs) with NRPV 
favored drug deposition in spleen and lymph node 
rather than kidney by four weeks post-injection [15]. 
Our findings recapitulate the notion that IV 
administration of NRPV enhances deposition in 
reticuloendothelial organs rather than those that 
facilitate drug excretion. Differences in particle 
biodistribution in non-lymphoid organs likely results 
from NRPV being nanoformulated with a poloxamer 
surfactant whereas EuS nanoprobes are encapsulated 
in cholesterol-based lipids. Future experiments will 
ensure that nanotheranostic compositions and route 
of administration is synchronized with those of 
nanoformulated antiretrovirals. 
EuS nanoprobe biotracking reveals three 
therapeutic parameters. First, nanoparticles should be 
made with long-axis diameters below ~ 350 nm. This 
will serve to ensure that any defined therapeutics do 
not become entrapped in pulmonary capillaries that 
not only blunt systemic dissemination but could pose 
risk of pulmonary and cardiac failure. On balance, 
nanoparticles size must exceed 24 nm to avert 
inducing disseminated intravascular coagulation [45]. 
Second, lipid components present in the particle’s 
protective shell, core or complexed with therapeutic 
payloads should be of sufficient hydrophobicity to 
permeate lymph nodes. Reaching lymph nodes, 
where latently-infected memory CD4+ T cells are 
predominantly located, is critical for any therapeutic 
strategy developed to sterilize virus in an infected 
host [46]. Third, any newly designed theranostic 
particles must mirror the physicochemical 
characteristics of antiretroviral prodrug nanocrystals, 
which show enhanced cell uptake and the slow ester 
hydrolysis of hydrocarbon promoieties, to parallel 
biodistribution patterns that now enable 90% 
inhibitory concentrations in plasma from months to 
up to one year [8]. 
Future investigations are planned to facilitate 
bench to bedside use of the EuS nanoprobes. First, 
intramuscular injection of EuS is required to simulate 
the route of long-acting antiretroviral administrations. 
Second, the utility of europium-153 fluorescence by 
confocal microscopy and flow cytometry must be 
employed to assess EuS uptake in divergent cell types. 
Third, serum enzyme profiles and histological 
assessments will need to be tested in order to 
determine potential EuS toxicity. Finally, the DSPE- 
PEG2000 lipid shell can be complexed to targeting 
ligands such as folic acid and tuftsin to evaluate 
whether surface modification improves particle 
delivery to lymphoid organs and the brain. 
Conclusions 
EuS nanoprobes retain multimodal molecular 
imaging potential for delivery of rod-shaped 
therapeutic nanomaterials to HIV-1 reservoir sites. 
Advantages to this composition include reduced 
requirement for transition metals in particle synthesis, 
which confers improved biocompatibility to EuS and 
lowers production cost. Taken together, this 
technology provides a platform to accelerate the pace 
of nanoformulated ART development and maximize 
delivery of therapeutics to viral cell and tissue 
reservoirs. 
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